(Q57071775)

Global control of hepatitis C: where challenge meets opportunity

21 January 2018

1 reference

Assembly of infectious hepatitis C virus particles

21 January 2018

1 reference

Ultrastructural analysis of hepatitis C virus particles

21 January 2018

1 reference

Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture

21 January 2018

1 reference

Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome

21 January 2018

1 reference

Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2

21 January 2018

1 reference

Hepatitis C Virus E2 Envelope Glycoprotein Core Structure

21 January 2018

1 reference

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

21 January 2018

1 reference

Role of low-density lipoprotein receptor in the hepatitis C virus life cycle

21 January 2018

1 reference

Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate

21 January 2018

1 reference

Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption

21 January 2018

1 reference

Low density lipoprotein receptor as a candidate receptor for hepatitis C virus

21 January 2018

1 reference

Binding of hepatitis C virus to CD81

21 January 2018

1 reference

The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

21 January 2018

1 reference

Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry

21 January 2018

1 reference

Human occludin is a hepatitis C virus entry factor required for infection of mouse cells

21 January 2018

1 reference

Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor

21 January 2018

1 reference

Identification of transferrin receptor 1 as a hepatitis C virus entry factor

21 January 2018

1 reference

Completion of the entire hepatitis C virus life cycle in genetically humanized mice

21 January 2018

1 reference

A genetically humanized mouse model for hepatitis C virus infection

21 January 2018

1 reference

Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.

21 January 2018

1 reference

Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps.

21 January 2018

1 reference

The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination

21 January 2018

1 reference

CD81 and Claudin 1 Coreceptor Association: Role in Hepatitis C Virus Entry

21 January 2018

1 reference

Protein Kinase A-Dependent Step(s) in Hepatitis C Virus Entry and Infectivity

21 January 2018

1 reference

CD81 Is a Central Regulator of Cellular Events Required for Hepatitis C Virus Infection of Human Hepatocytes

21 January 2018

1 reference

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy

21 January 2018

1 reference

HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex.

21 January 2018

1 reference

Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies

21 January 2018

1 reference

Border patrol intensifies for hepatitis C virus entry

21 January 2018

1 reference

A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo

21 January 2018

1 reference

Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo

21 January 2018

1 reference

Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors

21 January 2018

1 reference

Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals

21 January 2018

1 reference

A novel small molecule inhibitor of hepatitis C virus entry

21 January 2018

1 reference

(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry

21 January 2018

1 reference

The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry

21 January 2018

1 reference

A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes

21 January 2018

1 reference

Structure of a hepatitis C virus RNA domain in complex with a translation inhibitor reveals a binding mode reminiscent of riboswitches

21 January 2018

1 reference

Hepatitis C virus translation inhibitors targeting the internal ribosomal entry site.

21 January 2018

1 reference

Structural and Functional Studies of Nonstructural Protein 2 of the Hepatitis C Virus Reveal Its Key Role as Organizer of Virion Assembly

21 January 2018

1 reference

Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins

21 January 2018

1 reference

NS2 protein of hepatitis C virus interacts with structural and non-structural proteins towards virus assembly

21 January 2018

1 reference

Hepatitis C virus NS2 coordinates virus particle assembly through physical interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes

21 January 2018

1 reference

Regulation of hepatic innate immunity by hepatitis C virus

21 January 2018

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex

21 January 2018

1 reference

Ultrastructural and biochemical analyses of hepatitis C virus-associated host cell membranes

21 January 2018

1 reference

Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication

21 January 2018

1 reference

Sequential biogenesis of host cell membrane rearrangements induced by hepatitis C virus infection

21 January 2018

1 reference

Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment

21 January 2018

1 reference

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus

21 January 2018

1 reference

Remodeling of ribonucleoprotein complexes with DExH/D RNA helicases

21 January 2018

1 reference

Amphipathic alpha-helix AH2 is a major determinant for the oligomerization of hepatitis C virus nonstructural protein 4B

21 January 2018

1 reference

NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes

21 January 2018

1 reference

Hepatitis C replication inhibitors that target the viral NS4B protein

21 January 2018

1 reference

Highly potent HCV NS4B inhibitors with activity against multiple genotypes

21 January 2018

1 reference

Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.

21 January 2018

1 reference

Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus

21 January 2018

1 reference

The NS5A protein of hepatitis C virus is a zinc metalloprotein

21 January 2018

1 reference

Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase

21 January 2018

1 reference

Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain.

21 January 2018

1 reference

Identification of Residues Required for RNA Replication in Domains II and III of the Hepatitis C Virus NS5A Protein

21 January 2018

1 reference

Essential Role of Domain III of Nonstructural Protein 5A for Hepatitis C Virus Infectious Particle Assembly

21 January 2018

1 reference

Interaction of Hepatitis C Virus Nonstructural Protein 5A with Core Protein Is Critical for the Production of Infectious Virus Particles

21 January 2018

1 reference

Regulation of Hepatitis C Virion Production via Phosphorylation of the NS5A Protein

21 January 2018

1 reference

A hepatitis C virus NS5A phosphorylation site that regulates RNA replication

21 January 2018

1 reference

Insights into the complexity and functionality of hepatitis C virus NS5A phosphorylation

21 January 2018

1 reference

Treating hepatitis C infection by targeting the host

21 January 2018

1 reference

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.

21 January 2018

1 reference

Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein

21 January 2018

1 reference

NS5A inhibitors in the treatment of hepatitis C.

21 January 2018

1 reference

The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein

21 January 2018

1 reference

The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization.

21 January 2018

1 reference

Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action

21 January 2018

1 reference

Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052

21 January 2018

1 reference

Identification of Hepatitis C Virus NS5A Inhibitors

21 January 2018

1 reference

Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA.

21 January 2018

1 reference

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

21 January 2018

1 reference

Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.

21 January 2018

1 reference

Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.

21 January 2018

1 reference

The science of direct-acting antiviral and host-targeted agent therapy

21 January 2018

1 reference

Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?

21 January 2018

1 reference

Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides

21 January 2018

1 reference

Structure-activity relationships in the development of allosteric hepatitis C virus RNA-dependent RNA polymerase inhibitors: ten years of research

21 January 2018

1 reference

Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase

21 January 2018

1 reference

Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infection

21 January 2018

1 reference

Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase

21 January 2018

1 reference

New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development

21 January 2018

1 reference

Targets for antiviral therapy of hepatitis C.

21 January 2018

1 reference

Hepatitis C virus and host cell lipids: an intimate connection

21 January 2018

1 reference

Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication

21 January 2018

1 reference

Class III Phosphatidylinositol 4-Kinase Alpha and Beta Are Novel Host Factor Regulators of Hepatitis C Virus Replication

21 January 2018

1 reference

Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment

21 January 2018

1 reference

A Functional Genomic Screen Identifies Cellular Cofactors of Hepatitis C Virus Replication

21 January 2018

1 reference

Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening.

21 January 2018

1 reference

Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication

21 January 2018

1 reference

Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication.

21 January 2018

1 reference

The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A

21 January 2018

1 reference

Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity

21 January 2018

1 reference

Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target

21 January 2018

1 reference

Mapping of functional domains of the lipid kinase phosphatidylinositol 4-kinase type III alpha involved in enzymatic activity and hepatitis C virus replication

21 January 2018

1 reference

Targeting lipid metabolism in the treatment of hepatitis C virus infection

21 January 2018

1 reference

Different anti-HCV profiles of statins and their potential for combination therapy with interferon

21 January 2018

1 reference

Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids

21 January 2018

1 reference

Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication

21 January 2018

1 reference

Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation

21 January 2018

1 reference

Self-enhancement of hepatitis C virus replication by promotion of specific sphingolipid biosynthesis

21 January 2018

1 reference

Hepatitis C Virus RNA Replication Occurs on a Detergent-Resistant Membrane That Cofractionates with Caveolin-2

21 January 2018

1 reference

Sphingomyelin activates hepatitis C virus RNA polymerase in a genotype-specific manner

21 January 2018

1 reference

Host sphingolipid biosynthesis as a target for hepatitis C virus therapy

21 January 2018

1 reference

Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner.

21 January 2018

1 reference

Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets

21 January 2018

1 reference

Maturation of hepatitis C virus core protein by signal peptide peptidase is required for virus production

21 January 2018

1 reference

Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1

21 January 2018

1 reference

The lipid droplet is an important organelle for hepatitis C virus production

21 January 2018

1 reference

HCV core residues critical for infectivity are also involved in core-NS5A complex formation

21 January 2018

1 reference

Diacylglycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core

21 January 2018

1 reference

Rab18 binds to hepatitis C virus NS5A and promotes interaction between sites of viral replication and lipid droplets

21 January 2018

1 reference

Lipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A protein

21 January 2018

1 reference

A concerted action of hepatitis C virus p7 and nonstructural protein 2 regulates core localization at the endoplasmic reticulum and virus assembly

21 January 2018

1 reference

The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly

21 January 2018

1 reference

hepatitis c Virus p7 is critical for capsid assembly and envelopment

21 January 2018

1 reference

The ins and outs of hepatitis C virus entry and assembly

21 January 2018

1 reference

Trafficking of hepatitis C virus core protein during virus particle assembly

21 January 2018

1 reference

The ESCRT system is required for hepatitis C virus production

21 January 2018

1 reference

Vps4 and the ESCRT-III complex are required for the release of infectious hepatitis C virus particles

21 January 2018

1 reference

Regulation of hepatitis C virus secretion by the Hrs-dependent exosomal pathway.

21 January 2018

1 reference

Human Apolipoprotein E Is Required for Infectivity and Production of Hepatitis C Virus in Cell Culture

21 January 2018

1 reference

Cellular Determinants of Hepatitis C Virus Assembly, Maturation, Degradation, and Secretion

21 January 2018

1 reference

Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins

21 January 2018

1 reference

Apolipoprotein E but Not B Is Required for the Formation of Infectious Hepatitis C Virus Particles

21 January 2018

1 reference

Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles.

21 January 2018

1 reference

The association of hepatitis C virus glycoproteins with apolipoproteins E and B early in assembly is conserved in lipoviral particles

21 January 2018

1 reference

The C-terminal alpha-helix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virus

21 January 2018

1 reference

Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells.

21 January 2018

1 reference

Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly

21 January 2018

1 reference

Mouse hepatic cells support assembly of infectious hepatitis C virus particles

21 January 2018

1 reference

Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines

21 January 2018

1 reference

Role of conserved cysteine residues in hepatitis C virus glycoprotein e2 folding and function

21 January 2018

1 reference

Characterization of the envelope glycoproteins associated with infectious hepatitis C virus

21 January 2018

1 reference

Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production

21 January 2018

1 reference

Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel

21 January 2018

1 reference

Hepatitis C Virus p7 Protein Is Crucial for Assembly and Release of Infectious Virions

21 January 2018

1 reference

A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues.

21 January 2018

1 reference

Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors

21 January 2018

1 reference

Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle

21 January 2018

1 reference

MicroRNAs in common human diseases

21 January 2018

1 reference

Development of microRNA therapeutics is coming of age.

21 January 2018

1 reference

Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA

21 January 2018

1 reference

Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex.

21 January 2018

1 reference

Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122

21 January 2018

1 reference

Competing and noncompeting activities of miR-122 and the 5' exonuclease Xrn1 in regulation of hepatitis C virus replication.

21 January 2018

1 reference

miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1.

21 January 2018

1 reference

Liver-specific microRNA-122: Biogenesis and function

21 January 2018

1 reference

MicroRNA-targeting therapeutics for hepatitis C.

21 January 2018

1 reference

Miravirsen (SPC3649) can inhibit the biogenesis of miR-122.

21 January 2018

1 reference

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection

21 January 2018

1 reference

Treatment of HCV infection by targeting microRNA

21 January 2018

1 reference

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes

21 January 2018

1 reference

SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro

21 January 2018

1 reference

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

21 January 2018

1 reference

The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

21 January 2018

1 reference

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

21 January 2018

1 reference

Update on alisporivir in treatment of viral hepatitis C.

21 January 2018

1 reference

Profile of alisporivir and its potential in the treatment of hepatitis C.

21 January 2018

1 reference

Suppression of coronavirus replication by cyclophilin inhibitors

21 January 2018

1 reference

Hepatitis C Virus NS5A Protein Is a Substrate for the Peptidyl-prolyl cis/trans Isomerase Activity of Cyclophilins A and B

21 January 2018

1 reference

Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A.

21 January 2018

1 reference

DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A

21 January 2018

1 reference

Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics

21 January 2018

1 reference

Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex

21 January 2018

1 reference

Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation

21 January 2018

1 reference

Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses

21 January 2018

1 reference

Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV.

21 January 2018

1 reference

The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).

21 January 2018

1 reference

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

21 January 2018

1 reference

Toll-Like Receptor 3 Mediates Establishment of an Antiviral State against Hepatitis C Virus in Hepatoma Cells

21 January 2018

1 reference

Interferon-alfa, interferon-lambda and hepatitis C.

21 January 2018

1 reference

Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection

21 January 2018

1 reference

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

New hepatitis C therapies: the toolbox, strategies, and challenges

21 January 2018

1 reference

Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7

21 January 2018

1 reference